Treanda regulatory update

SymBio said South Korea’s Ministry of Food and Drug Safety (MFDS) approved an NDA to expand the label of bendamustine to include treatment of relapsed or refractory low-grade non-Hodgkin’s lymphoma (NHL). Eisai’s Eisai Korea Inc. subsidiary already markets the drug in the country to treat chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). ...